Open AccessTreatment Patterns and Clinical Outcomes of Chronic Urticaria: Two-year Follow-up Results from the Scandinavian AWARE Study
Author(s) -
Simon Francis Thomsen,
Ellen Cathrine Pritzier,
Chris Anderson,
Siri Juvik,
Nicolas V Baust,
Rikke Dodge,
Anna-Karin Dahlborn,
Christian Vestergaard
Publication year - 2022
Publication title -
acta dermato-venereologica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.982
H-Index - 83
eISSN - 1651-2057
pISSN - 0001-5555
DOI - 10.2340/actadv.v102.1620
Subject(s) - antihistamine , medicine , refractory (planetary science) , quality of life (healthcare) , chronic urticaria , disease , chronic disease , physical therapy , intensive care medicine , immunology , physics , nursing , astrobiology
The AWARE (A World-wide Antihistamine-Refractory chronic urticaria patient Evaluation) study investigated outcomes in patients with chronic urticaria refractory to H1-antihistamine. The objective of the current study was to analyse the effects of treatment on patients’ symptoms and quality of life for a period of up to 2 years. Over the 2 years, there was clear improvement in the high rates of disease burden from baseline, as evidenced by lower scores for disease severity scales, better quality of life, and a decreasing rate of medical resource utilization. However, this is the result of treatment adherence to the guidelines in highly specialized Scandinavian urticaria centres, and has its basis in the relatively low treatment intensity and control at enrolment. There is a need for greater adherence to the treatment guidelines and better management of antihistamine-refractory chronic urticaria.